Clinical Trial Update: Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) [Phase 3]

View source ↗

Summary

Phase 3 GEMINI 1 trial of the BTK inhibitor tolebrutinib (SAR442168) for relapsing multiple sclerosis has completed enrollment, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Tolebrutinib (tolebrutinib)

Snippet

Sponsor: Sanofi | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2025-06-18